Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2019 /
Comment: Immunotherapy combination for advanced NSCLC

27th Sep - 1st Oct 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.09.19
Views: 504

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Dr Marina Garassino speaks to ecancer at ESMO 2019 in Barcelona commenting on the CheckMate-227 trial, which uses nivolumab plus low-dose ipilimumab to treat patients with advanced non-small cell lung cancer (NSCLC).

She explains that the results of the study suggest that this combination may provide an alternative to chemotherapy in the first-line setting.

Dr Garassino comments that while this is a promising treatment option, clinicians need to better understand which patients are best suited to chemotherapy, immunotherapy or chemotherapy plus immunotherapy, taking toxicities into account.

Watch the press conference here.

Watch Dr Marina Garassino's comment here.

Read more about the study's here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation